Literature DB >> 28268065

A second chance for success with BRAF and MEK inhibitors in melanoma.

Kelly G Paulson1, John A Thompson2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28268065     DOI： 10.1016/S1470-2045(17)30151-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy.

Authors:  Huan Yu; Meng Ma; Junya Yan; Longwen Xu; Jiayi Yu; Jie Dai; Tianxiao Xu; Huan Tang; Xiaowen Wu; Siming Li; Bin Lian; Lili Mao; Zhihong Chi; Chuanliang Cui; Jun Guo; Yan Kong
Journal:  J Transl Med       Date:  2017-12-04       Impact factor: 5.531

2.  Immunotherapy Outcomes in Advanced Melanoma in Relation to Age.

Authors:  Krishna Joshi; Dinesh Atwal; Rahul Ravilla; Yadav Pandey; Naveen Yarlagadda; Sunil Kakadia; Issam Makhoul; Laura Hutchins; Fade Mahmoud
Journal:  Perm J       Date:  2020-02-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.